PAR 7.69% 21.0¢ paradigm biopharmaceuticals limited..

"About a month after my treatment their was no white spots", page-36

  1. 200 Posts.
    lightbulb Created with Sketch. 383
    I don’t believe so. My belief is that any pentosan product that is close to the Bene material in some gross structural parameters will be effective.

    Those parameters being principally molecular weight (or degree of polymerisation if you prefer), degree of sulfation, and side branch pattern. As I’ve written before, PPS is not a distinct molecule but a mixture of many different molecules in the same family that span across ranges of these parameters. Another PPS product that substantially overlaps that range will, in my opinion, have a similar therapeutic profile.

    What makes Bene’s product special is not that it’s the only one that works, but that it’s the only one that is registered. It’s not hard (in a relative sense, it’s actually a huge amount of work) to produce an ingredient that has, say, the same average MW as Zilosul. But in order to be accepted by the FDA it would have to match the full molecule weight distribution in detail. Now that’s hard, in both relative and absolute senses. The same concept would apply simultaneously to the other structural characteristics like degree of sulfation.

    So I would be confident that vet PPS for equines would be every bit as effective in humans as Zilosul. What makes Zilosul special is not it’s effectiveness, but the legal and regulatory framework that allows it to be made available to humans, which is also a wide and deep moat against competitors.

    All in my opinion, obviously I don’t have access to the proprietary data packs for these products.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.